CLAIMS

Claim 1. An antibody drug conjugate (ADC) comprising a NMT inhibitor conjugated to an antibody *via* a linker, or a salt thereof, wherein the NMT inhibitor is a compound of formula (VI):



(VI)

wherein:

R^1 is a group of formula O-L-A;

L is $–(CHR^{12})_m$-;

each R^{12} is independently H or C_{1-4}alkyl;

m is 1, 2 or 3;

A is:



v is 0, 1 or 2;

R^{9a} is H, C_{1-4}alkyl or C_{1-4}haloalkyl;

R^{9b} is H, C_{1-4}alkyl or C_{1-4}haloalkyl;

R^{9c} is C_{1-4}alkyl or C_{1-4}haloalkyl;

R^{9d} is H, C_{1-4}alkyl or C_{1-4}haloalkyl;

R^{10} is H, C_{1-4}alkyl or C_{1-4}haloalkyl;

R^{11} is H, halo, CN, C_{1-4}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy or C_{1-4}haloalkoxy;

s is 0, 1, 2 or 3;

each R^2 is independently F, Cl, Br, C_{1-4}alkyl optionally substituted by up to 3 halogen groups, OCH_3 or OCF_3;

Y is CH or C_{1-4}alkyl;

R^3 is H or C_{1-4}alkyl;

R^4 is H or C_{1-4}alkyl;

R^5 is H;

R^6 is H or C_{1-4}alkyl;

q is 0 or 1;

R^7 is H or methyl;

R^8 is H or methyl;

or R^3 and R^6 and the intervening atoms form a 3 to 7 membered non-aromatic heterocycle composed of the intervening atoms and bond, or the intervening atoms and $–(CHR^a)_r–$; or the R^7 group and the R^6 group and the intervening atoms form a 3 to 7 membered non-aromatic heterocycle composed of the intervening atoms and $–(CHR^a)_r–$;

r is 1, 2, 3, 4 or 5; and

R^a is hydrogen or methyl,

or a salt thereof.

Claim 2. The salt of an ADC according to claim 1.

Claim 3. The salt according to claim 1 or 2, which is a pharmaceutically acceptable salt.

Claim 4. The ADC according to claim 1.

Claim 5. The ADC or salt thereof according to any one of claims 1 to 4, wherein the NMT inhibitor is a compound of formula (VIA):



(VIA),

wherein:

R^{2a} is H or F;

R^{2b} is F;

R^{5a} is H;

R^{6a} is H or methyl;

R^{9ca} is methyl, *iso*-propyl or *tert*-butyl;

R^{9cb} is H or methyl;

R^{10a} is methyl; and

R^{11a} is methyl;

provided that when R^{2a} is H, R^{9cb} is H,

or a salt thereof.

Claim 6. The ADC or salt thereof according to any one of claims 1 to 5, wherein the NMT inhibitor is 1-{4-[2-(2,3-difluoro-6-{3-[(methylamino)methyl]imidazo[1,2-a]pyridin-6-yl}phenoxy)ethyl]-1,5-dimethyl-1H-pyrazol-3-yl}-2,2-dimethylpropan-1-ol:



,

or a salt thereof.

Claim 7. The ADC or salt thereof according to claim 6, wherein the NMT inhibitor is 1-{4-[2-(2,3-difluoro-6-{3-[(methylamino)methyl]imidazo[1,2-a]pyridin-6-yl}phenoxy)ethyl]-1,5-dimethyl-1H-pyrazol-3-yl}-2,2-dimethylpropan-1-ol, wherein the NMT inhibitor is the isomer having the stereochemical arrangement of:



,

or a salt thereof.

Claim 8. The ADC or salt thereof according to claim 6, wherein the NMT inhibitor is 1-{4-[2-(2,3-difluoro-6-{3-[(methylamino)methyl]imidazo[1,2-a]pyridin-6-yl}phenoxy)ethyl]-1,5-

dimethyl-1H-pyrazol-3-yl}-2,2-dimethylpropan-1-ol, wherein the NMT inhibitor is the isomer having the stereochemical arrangement of:



or a salt thereof.

Claim 9. The ADC or salt thereof according to any one of claims 1 to 5, which is 2-{4-[2-(2,3-difluoro-6-{3-[(methylamino)methyl]imidazo[1,2-a]pyridin-6-yl}phenoxy)ethyl]-1,5-dimethyl-1H-pyrazol-3-yl}propan-2-ol:



or a salt thereof.

Claim 10. The ADC or salt thereof according to any one of claims 1 to 9, wherein the linker has the following formula (VII):

$-A_a-W_w-Y_y-$ (formula (VII))

wherein:

A is a first stretcher unit which when present forms a covalent bond with a chain terminus (such as a N-terminus) or a functional group of an amino acid side chain of the antibody;

a is 0 or 1;

each W is independently an amino acid unit or a glucuronide unit which when A and/or Y are absent forms a covalent bond with a chain terminus (such as a N-terminus) or a functional group of an amino acid side chain of the antibody and/or with a functional group of the NMT inhibitor respectively;

when W is an amino acid, w is 1 to 12;

when W is a glucuronide unit, w is 1 or 2;

Y is a second stretcher unit which when present forms a covalent bond with a functional group of the NMT inhibitor; and

y is 0 or 1.

Claim 11. The ADC or salt thereof according to any one of claims 1 to 10, wherein the linker has the formula (LI):



(LI),

wherein ~~~ denotes the point of attachment to a chain terminus (such as a N-terminus) or a functional group on an amino acid side chain of the antibody; and

⁄⁄ denotes the point of attachment to a functional group of the NMT inhibitor.

Claim 12. The ADC or salt thereof according to any one of claims 1 to 10, wherein the linker has the formula (LII):



,

wherein ~~~ denotes the point of attachment to a chain terminus (such as a N-terminus) or a functional group on an amino acid side chain of the antibody; and

⁄⁄ denotes the point of attachment to a functional group of the NMT inhibitor.

Claim 13. The ADC or salt thereof according to any one of claims 1 to 9, wherein the linker has the formula (LIII):



wherein ~ denotes the point of attachment to a chain terminus (such as a N-terminus) or a functional group on an amino acid side chain of the antibody; and

⋰ denotes the point of attachment to a functional group of the NMT inhibitor.

Claim 14. The ADC or salt thereof according to any one of claims 1 to 9, wherein the linker has the formula (LIV):



wherein ~ denotes the point of attachment to a chain terminus (such as a N-terminus) or a functional group on an amino acid side chain of the antibody; and

⁄⁄ denotes the point of attachment to a functional group of the NMT inhibitor.

Claim 15. The ADC or salt thereof according to any one of claims 10 to 14, wherein the functional group on the amino acid side chain of the antibody is a sulfhydryl.

Claim 16. The ADC or salt thereof according to any one of claims 10 to 14, wherein the functional group on the NMT inhibitor is an amino or alcohol, for example an amino.

Claim 17. The ADC or salt thereof according to any one of claims 1 to 16, wherein the antibody is a humanised, chimeric, human antibody or an antibody fragment.

Claim 18. The ADC or salt thereof according to claim 17, wherein the antibody binds to HER2.

Claim 19. The ADC or salt thereof according to claim 18, wherein the antibody is trastuzumab, pertuzumab, margetuximab, ertumaxomab, MM-111, MCLA-128, ZW25, MDX-210, ado-trastuzumab or fam-trastuzumab.

Claim 20. The ADC or salt thereof according to claim 19, wherein the antibody is trastuzumab.

Claim 21. The ADC or salt thereof according to claim 18, wherein the antibody has the CDRs of the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2.

Claim 22. The ADC or salt thereof according to claim 17, wherein the antibody binds to CD20.

Claim 23. The ADC or salt thereof according to claim 22, wherein the antibody is rituximab.

Claim 24. The ADC or salt thereof according to claim 17, wherein the antibody binds to Trop-2.

Claim 25. The ADC or salt thereof according to claim 24, wherein the antibody is sacituzumab.

Claim 26. The ADC or salt thereof according to claim 17, wherein the antibody binds to B7-H3.

Claim 27. The ADC or salt thereof according to claim 26, wherein the antibody is ifinatamab.

Claim 28. The ADC or salt thereof according to any one of claims 1 to 27, wherein the drug loading (p) of NMT inhibitor to antibody is between 1 to 10 NMT inhibitor(s) to antibody, such as between 2 and 6, 4 and 6, 8 and 10, or 6 and 8 NMT inhibitors to antibody.

Claim 29. The ADC or salt thereof according to any one of claims 1 to 28, wherein the ADC or salt thereof comprises the following formula:



,

or a salt thereof, wherein Ab is an antibody as defined in any one of claims 1 to 27 and p is the drug loading of NMT inhibitor as defined in claim 28.

Claim 30. The ADC or salt thereof according to any one of claims 1 to 28, wherein the ADC or salt thereof comprises the following formula:



or a salt thereof, wherein Ab is an antibody as defined in any one of claims 1 to 27 and p is the drug loading of NMT inhibitor as defined in claim 28.

Claim 31. The ADC or salt thereof according to any one of claims 1 to 28, wherein the ADC or salt thereof comprises the following formula:



wherein Ab is an antibody as defined in any one of claims 1 to 27 and p is the drug loading of NMT inhibitor as defined in claim 28.

Claim 32. The ADC or salt thereof according to any one of claims 1 to 28, wherein the ADC or salt thereof comprises the following formula:



wherein Ab is an antibody as defined in any one of claims 1 to 27 and p is the drug loading of NMT inhibitor as defined in claim 28.

Claim 33. The ADC or salt thereof according to any one of claims 29 to 32, wherein the ADC or salt thereof is bound to the antibody via a sulfhydryl group on the side chain of an amino acid on the antibody.

Claim 34. A pharmaceutical composition comprising the ADC or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 33.

Claim 35. The ADC or pharmaceutically acceptable salt thereof according to any one of claims 1 to 33, or the pharmaceutical composition according to claim 34, for use as a medicament.

Claim 36. The ADC or pharmaceutically acceptable salt thereof, or pharmaceutical composition, for use according to claim 35, for use in the prevention or treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect.

Claim 37. The ADC or pharmaceutically acceptable salt thereof, or pharmaceutical composition, for use according to claim 36, wherein the disease or disorder is a hyperproliferative disorder, and wherein the hyperproliferative disorder is cancer.

Claim 38. The ADC or pharmaceutically acceptable salt thereof, or pharmaceutical composition, for use according to claim 37 wherein the cancer is breast cancer, bladder

cancer, lung cancer, prostate cancer, kidney cancer, esophageal carcinoma, colorectal cancer, gallbladder carcinoma, brain tumor, lymphoma, leukemia or neuroblastoma.

Claim 39. The ADC or pharmaceutically acceptable salt thereof, or pharmaceutical composition, for use according to claim 37, wherein the cancer is a haematologic malignancy or a solid-tumor.

Claim 40. A drug conjugate or salt and/or solvate thereof comprising a NMT inhibitor and a linker, wherein the linker comprises a group capable of forming a covalent bond to a chain terminus (such as a N-terminus) or a functional group on an amino acid side chain of an antibody e.g. a sulfhydryl group, wherein the NMT inhibitor is as defined in any one of claims 1 to 9.

Claim 41. The drug conjugate, salt and/or solvate thereof according to claim 40, wherein the drug conjugate has the formula (DC-2):



(DC-2),

or a salt and/or solvate thereof, wherein NMT is an NMT inhibitor as defined in any one of claims 1 to 9.

Claim 42. The drug conjugate, salt and/or solvate thereof according to claim 41, which is (1S,2R,3S,4R,5R)-5-(4-{[({[6-(3,4-difluoro-2-{2-[3-(1-hydroxy-2,2-dimethylpropyl)-1,5-dimethyl-1H-pyrazol-4-yl]ethoxy}phenyl)imidazo[1,2-a]pyridin-3yl]methyl}(methyl)carbamoyl)oxy]methyl}-2-[3-(3-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}propanamido)propanamido]phenoxy)-3,4-dihydroxy-2-methylcyclohexane-1-carboxylic acid:



,

or a salt and/or solvate thereof.

Claim 43. The drug conjugate, salt and/or solvate thereof according to claim 41, which is:



or a salt and/or solvate thereof.

Claim 44. The drug conjugate, salt and/or solvate thereof according to claim 40, wherein the drug conjugate has the formula (DC-1):



(DC-1),

or a salt and/or solvate thereof, wherein NMT is an NMT inhibitor as defined in any one of claims 1 to 9.

Claim 45. The drug conjugate, salt and/or solvate thereof according to claim 44, which is {4-[(2S)-5-(carbamoylamino)-2-[(2S)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]-3-methylbutanamido] pentanamido]phenyl}methyl N-{[6-(3,4-difluoro-2-{2-[3-(1-hydroxy-2,2-dimethylpropyl)-1,5-dimethyl-1H-pyrazol-4-yl]ethoxy}phenyl)imidazo[1,2-a]pyridin-3-yl]methyl}-N-methylcarbamate:



,

or a salt and/or solvate thereof.

Claim 46. The drug conjugate, salt and/or solvate thereof according to claim 40, wherein the drug conjugate has the formula (DC-5):



(DC-5),

or a salt and/or solvate thereof, wherein NMT is an NMT inhibitor as defined in any one of claims 1 to 9.

Claim 47. The drug conjugate, salt and/or solvate thereof according to claim 46, which is:



or a salt and/or solvate thereof.

Claim 48. The drug conjugate, salt and/or solvate thereof according to claim 40, wherein the drug conjugate has the formula (DC-6):



(DC-6),

or a salt and/or solvate thereof, wherein NMT is an NMT inhibitor as defined in any one of claims 1 to 9.

Claim 49. A compound selected from the group consisting of:

- a compound of formula (ADC-I):



(ADC-I); and

- a compound of formula (ADC-II):



(ADC-II),

wherein NMT is an NMT inhibitor as defined in any one of claims 1 to 9,
or a salt and/or solvate of any one thereof.